Xie Z - Search Results

1

Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia.

Mims A, Xie Z, Potluri R, Rotter D, Chevli M, Prebet T, Gaugler L, Strocchia M, Vasconcelos A, Sieluk J. Mims A, et al. Among authors: xie z. Leuk Lymphoma. 2024 Nov 28:1-9. doi: 10.1080/10428194.2024.2425792. Online ahead of print. Leuk Lymphoma. 2024. PMID: 39606887

2

Frontline treatment options for higher-risk MDS: can we move past azacitidine?

Sallman DA, Xie Z. Sallman DA, et al. Among authors: xie z. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):65-72. doi: 10.1182/hematology.2023000421. Hematology Am Soc Hematol Educ Program. 2023. PMID: 38066872 Free PMC article.

3

An overview of novel therapies in advanced clinical testing for acute myeloid leukemia.

Venugopal S, Xie Z, Zeidan AM. Venugopal S, et al. Among authors: xie z. Expert Rev Hematol. 2023 Feb;16(2):109-119. doi: 10.1080/17474086.2023.2174521. Epub 2023 Feb 8. Expert Rev Hematol. 2023. PMID: 36718500

4

What's Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach.

Awada H, Gurnari C, Xie Z, Bewersdorf JP, Zeidan AM. Awada H, et al. Among authors: xie z. Cancers (Basel). 2023 Apr 12;15(8):2248. doi: 10.3390/cancers15082248. Cancers (Basel). 2023. PMID: 37190176 Free PMC article. Review.

5

Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution.

Santinelli E, Pascale MR, Xie Z, Badar T, Stahl MF, Bewersdorf JP, Gurnari C, Zeidan AM. Santinelli E, et al. Among authors: xie z. Blood Rev. 2023 Nov;62:101130. doi: 10.1016/j.blre.2023.101130. Epub 2023 Aug 29. Blood Rev. 2023. PMID: 37679263 Review.

6

Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities.

Horvat NP, Abdallah EF, Xie Z, Al Ali N, Yun S, Walker A, Padron E, Sallman D, Chan O, Lancet J, Komrokji R, Kuykendall AT. Horvat NP, et al. Among authors: xie z. Ann Hematol. 2024 Jan;103(1):117-123. doi: 10.1007/s00277-023-05564-0. Epub 2023 Nov 30. Ann Hematol. 2024. PMID: 38030891

7

Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment.

Bewersdorf JP, Xie Z, Zeidan AM. Bewersdorf JP, et al. Among authors: xie z. Cancer J. 2023 May-Jun 01;29(3):195-202. doi: 10.1097/PPO.0000000000000658. Cancer J. 2023. PMID: 37195776

8

Are DDX41 variants of unknown significance and pathogenic variants created equal?

Xie Z, Starczynowski DT. Xie Z, et al. Haematologica. 2023 Nov 1;108(11):2883-2885. doi: 10.3324/haematol.2023.283416. Haematologica. 2023. PMID: 37317927 Free PMC article. No abstract available.

9

Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms.

Xie Z, Chen EC, Mendez LM, Komrokji R, Zeidan AM. Xie Z, et al. Cancer J. 2023 May-Jun 01;29(3):130-137. doi: 10.1097/PPO.0000000000000656. Cancer J. 2023. PMID: 37195768 Review.

10

Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms.

Stempel JM, Xie Z, Bewersdorf JP, Stahl M, Zeidan AM. Stempel JM, et al. Among authors: xie z. Cancer J. 2023 May-Jun 01;29(3):203-211. doi: 10.1097/PPO.0000000000000666. Cancer J. 2023. PMID: 37195777 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12,459 results

Search Page

Filters